Navigation Links
ImpediMed and Metagenics Announce Agreement
Date:10/2/2008

BRISBANE, Australia and SAN CLEMENTE, Calif., Oct. 2 /PRNewswire/ -- ImpediMed Ltd, a pioneer in the medical applications of bioimpedance technology and Metagenics, Inc., a global leader in science-based nutraceutical products, medical foods, and therapeutic lifestyle change programs, today announced an agreement to distribute ImpediMed technology in the United States and Canada. Metagenics' Australian affiliate, Health World, Ltd, has been a long-standing customer of the Brisbane-based medical device manufacturer.

"We've seen the synergies of combining ImpediMed's products for assessing fat and fluid status with our own research-based health and wellness products and programs, which we market to healthcare professionals," said Mike Katke, VP of Medical Marketing for San Clemente, California-based Metagenics. "Their scientifically-grounded approach and the reliability and portability of their technology made offering ImpediMed to our customers a simple decision."

ImpediMed CEO Greg Brown said, "Metagenics has been an outstanding Australian partner using ImpediMed's body composition analysis devices for several years. This expanded relationship makes sense in light of our mutual focus on addressing wellness and healthier life styles."

About Metagenics, Inc.

Metagenics, Inc. is a life sciences company and leading developer and manufacturer of science-based nutraceuticals medical foods, and therapeutic lifestyle change programs marketed to healthcare practitioners worldwide. It is headquartered in San Clemente, Calif. with manufacturing and multiple research facilities located in Gig Harbor, Wash., including its MetaProteomics(R) Nutrigenomics Research Center and its Functional Medicine Research Center(SM) for human clinical research. Metagenics holds multiple proprietary formula patents and produces over 400 research-based products to optimize health. The company demonstrates its commitment to purity and quality through its certifications for Good Manufacturing Practices (GMP) from the NPA, NSF International, and TGA. For more information about Metagenics, please visit http://www.metagenics.com.

About ImpediMed Limited

ImpediMed Limited develops and globally markets medical device systems for use in non-invasive screening and monitoring of fluid status and body composition. ImpediMed's product range includes medical devices for body composition analysis and early detection and monitoring of secondary lymphedema in cancer survivors. ImpediMed's products are TGA and FDA cleared as well as CE marked for global distribution. For more information about ImpediMed, please visit http://www.impedimed.com

Contact:

Joseline Davison

Metagenics, Inc.

949-369-3406

josiedavison@metagenics.com

Jack Butler

ImpediMed

585-248-2554

jbutler@impedimed.com


'/>"/>
SOURCE ImpediMed Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
3. 2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced
4. BioSpace and BIOCOM Announce 2009 Biotech Beach(TM) Hotbed Campaign
5. Synthetech Announces New Director of Manufacturing
6. onTargetjobs and ClearedConnections Announce Online Recruitment Partnership
7. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
8. Biotel Announces Record Revenues and Earnings for Fiscal 2008
9. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
10. Helix BioPharma Announces $11.4 Million Private Placement
11. ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):